MedTrace Logo

A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

NCT05415462 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6102

Last updated 2024-09-24

Study results available
· View outcomes & findings →

Summary

The primary objectives of this study are to evaluate the humoral immunogenicity of mRNA-1010 relative to that of an active comparator against vaccine-matched influenza A and B strains at Day 29, and to evaluate the safety and reactogenicity of mRNA-1010.

Conditions

Interventions

BIOLOGICAL

mRNA-1010

Sterile liquid for injection

BIOLOGICAL

Fluarix Tetra

Sterile suspension for injection

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-06
Primary Completion
2023-09-04
Completion
2023-09-04
FDA Drug
Yes

Countries

  • Argentina
  • Australia
  • Colombia
  • Panama
  • Philippines

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05415462 on ClinicalTrials.gov